Bousquet M, Noirot C, Accadbled F, Sales de Gauzy J, Castex M P, Brousset P, Gomez-Brouchet A
Cancer Research Center of Toulouse, INSERM U1037, laboratoire d'excellence Labex TOUCAN, Toulouse.
Genotoul Bioinfo, INRA, Castanet Tolosan.
Ann Oncol. 2016 Apr;27(4):738-44. doi: 10.1093/annonc/mdw009. Epub 2016 Jan 19.
Whole-genome sequencing studies have recently shown that osteosarcomas (OSs) display high rates of structural variation, i.e. they contain many somatic mutations and copy number alterations. TP53 and RB1 show recurrent somatic alterations in concordant studies, suggesting that they could be key players in bone oncogenesis.
we carried out whole-genome sequencing of DNA from seven high-grade OS samples matched with normal tissue from the same patients.
We confirmed the presence of genetic alterations of the TP53 (including novel unreported mutations) and RB1 genes. Most interestingly, we identified a total of 84 point mutations and 4 deletions related to 82 different genes in OS samples, of which only 15 have been previously reported. Interestingly, the number of mutated genes (ranging from 4 to 8) was lower in TP53mut cases compared with TP53wt cases (ranging from 14 to 45). This was also true for the mutated RB1 case. We also observed that a dedifferentiated OS harboring MDM2 amplification did not carry any other mutations.
This study suggests that bone oncogenesis driven by TP53 or RB1 mutations occurs on a background of relative genetic stability and that the dedifferentiated OS subtype represents a clinico-pathological entity with distinct oncogenic mechanisms and thus requires different therapeutic management.
全基因组测序研究最近表明,骨肉瘤(OS)显示出较高的结构变异率,即它们包含许多体细胞突变和拷贝数改变。在一致性研究中,TP53和RB1显示出复发性体细胞改变,表明它们可能是骨肿瘤发生的关键因素。
我们对来自7个高级别OS样本的DNA进行了全基因组测序,并将其与同一患者的正常组织进行匹配。
我们证实了TP53(包括新的未报道的突变)和RB1基因存在基因改变。最有趣的是,我们在OS样本中总共鉴定出与82个不同基因相关的84个点突变和4个缺失,其中只有15个先前已有报道。有趣的是,与TP53野生型(TP53wt)病例(范围为14至45个)相比,TP53突变型(TP53mut)病例中的突变基因数量(范围为4至8个)更少。RB1突变病例也是如此。我们还观察到,携带MDM2扩增的去分化OS没有任何其他突变。
本研究表明,由TP53或RB1突变驱动的骨肿瘤发生是在相对遗传稳定性的背景下发生的,并且去分化OS亚型代表了具有独特致癌机制的临床病理实体,因此需要不同的治疗管理。